Start: September 1, 2017
End: May 31, 2024
This phase 4 clinical trial will test lithium, a drug approved to treat mania, depression, and other mental disorders, as a possible treatment that may delay dementia onset or slow its progression in older adults with mild cognitive impairment (MCI). Participants will be randomly assigned to take either lithium (beginning at 150 mg per day) or a placebo for two years. Participants will receive a neurocognitive assessment, biomarker tests using blood and cerebrospinal fluid samples, and brain imaging, at the start and after each year of the study.
Minimum Age: 60 Years
Maximum Age: N/A
Contact study personnel listed either under the general study contact or the location nearest you.
Lead: Ariel Gildengers, MD
Source: ClinicalTrials.gov ID: NCT03185208